From the Journals

COVID-19 antibody response not reduced with diabetes

Publish date: October 20, 2020

 

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Dapagliflozin’s CKD performance sends heart failure messages
MDedge Endocrinology
Time to screen for liver disease in type 2 diabetes?
MDedge Endocrinology
PPIs associated with diabetes risk, but questions remain
MDedge Endocrinology
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
MDedge Endocrinology
Empagliflozin cut PA pressures in heart failure patients
MDedge Endocrinology
T2D treatments create tension between glycemic and cardiovascular goals
MDedge Endocrinology
Entresto halves renal events in preserved EF heart failure patients
MDedge Endocrinology
Substance in tears could be used for diabetes monitoring
MDedge Endocrinology
Recall widens for diabetes drug metformin
MDedge Endocrinology
Diabetic neuropathic pain linked to brain bioenergic anomalies
MDedge Endocrinology